• Molecular NameImiquimod
  • Synonymimiquimod; Imiquimod acetate
  • Weight240.31
  • Drugbank_IDDB00724
  • ACS_NO99011-02-6
  • Show 3D model
  • LogP (experiment)2.103
  • LogP (predicted, AB/LogP v2.0)2.9
  • pkaN/A
  • LogD (pH=7, predicted)2.43
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.94
  • LogSw (predicted, AB/LogsW2.0)0.04
  • Sw (mg/ml) (predicted, ACD/Labs)0.02
  • No.of HBond Donors2
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds2
  • TPSA56.73
  • StatusFDA approved
  • AdministrationTopical
  • PharmacologyA prescription medication that acts as an immune response modifier.
  • Absorption_valueN/A
  • Absorption (description)Well absorbed through skin (as a cream)
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half life30 h (topical dose), 2 h (subcutaneous dose)
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include flu-like symptoms, such as fever, fatigue, headache, nausea, diarrhoea and muscle pain.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A